Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol PR in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2016
At a glance
- Drugs Tapentadol (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Grunenthal
- 19 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 16 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.